Enliven Therapeutics Reveals Exciting ELVN-001 Data Updates
Enliven Therapeutics Announces ELVN-001 Phase 1a Data Presentation
Enliven Therapeutics, Inc. (ELVN), a dynamic clinical-stage precision oncology company, has recently shared important updates regarding their promising investigational drug, ELVN-001. This announcement follows the selection of ELVN-001 data for oral presentation at a notable conference dedicated to chronic myeloid leukemia (CML). The European Society of Hematology International Chronic Myeloid Leukemia Foundation's 26th Annual John Goldman Conference is scheduled to take place in late September.
Understanding ELVN-001's Role in CML
ELVN-001 is engineered to be a highly selective small molecule kinase inhibitor, which is a significant advancement in treatments for CML patients. Its specific design targets the BCR-ABL gene fusion, which is known to drive the cancer's progression. This targeted approach may offer new hope for patients battling this challenging condition.
Presentation Details and Key Information
During the conference, the presentation of the updated data on ELVN-001 will be undertaken by Dr. Fabian Lang from Goethe University Hospital. The specifics are as follows:
- Title: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML
- Session: Scientific Session 5: New drugs and combinations
- Date & Time: September 28, 2024, from 3:00 p.m. to 4:20 p.m. CEST, with Dr. Lang's presentation scheduled from 3:35 p.m. to 3:50 p.m. CEST
Accessing the Presentation
For those interested in reviewing the details shared during the presentation, you can find a copy available on Enliven Therapeutics' official website in the Program Presentations & Publications section after the conference.
About Enliven Therapeutics
Enliven Therapeutics stands at the forefront of biopharmaceutical innovation, with a mission that extends beyond treating cancer to improving patients' quality of life. Their focus on small molecule inhibitors aims to meet not just the current, but also the evolving needs of cancer patients, highlighting their commitment to precision oncology. Through deep understanding of validated biological targets and unique chemical design, Enliven strives to develop therapies that could become best-in-class treatments in the oncology landscape.
Connecting with Enliven Therapeutics
For inquiries related to investment opportunities, Enliven Therapeutics encourages investors to reach out via the company's designated email address: ir@enliventherapeutics.com. Additionally, media representatives can connect with the company through media@enliventherapeutics.com for further information and assistance.
Frequently Asked Questions
What is the purpose of the ELVN-001 clinical trial?
The ELVN-001 clinical trial aims to evaluate the safety and effectiveness of this targeted therapy for treating chronic myeloid leukemia.
Who is presenting the ELVN-001 data at the conference?
Dr. Fabian Lang of Goethe University Hospital will present the updated Phase 1a data.
Where can I find the updated presentation details?
Presentation details will be available on Enliven Therapeutics’ website in the Program Presentations & Publications section after the conference.
What is Enliven Therapeutics’ main focus?
Enliven focuses on discovering and developing small molecule inhibitors to improve cancer treatment outcomes and patient quality of life.
How can I contact Enliven Therapeutics for investor relations?
Investors can contact Enliven Therapeutics via the email address ir@enliventherapeutics.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- UCB Reports Groundbreaking Two-Year Efficacy Data for BIMZELX
- Ovid Therapeutics' OV329 Shows Promise in Preclinical Trials
- Lyra Therapeutics Shares Insights from CRS Studies at Major Events
- Nordea's Transition to New Data Source for Rate Calculations
- Unpacking Travere Therapeutics' Future: Insights and Impact
- Exciting Announcements in Retail You Shouldn't Miss
- Exciting Plans for the 3rd Annual US Army Bowl National Combine
- Market Anticipation Grows with Inflation Data on the Horizon
- Exciting Growth Ahead for the Ceramic Fiber Market
- Lenz Therapeutics Innovations Aim to Transform Eye Care Market
Recent Articles
- Exciting Developments in Lithium Royalty Corp.'s Future Projects
- SciSparc Advances Toward Clinical Trial for Tourette Treatment
- Lincoln Financial Honors Legacy of Board Member Michael Mee
- ECD Automotive Design Welcomes New CFO and Board Chairperson
- Morningstar Announces Consistent Dividend Payout for Investors
- Kayne Anderson Energy Infrastructure Fund Secures $100 Million
- Tupperware Brands Faces Delisting from NYSE: Understanding the Process
- Steelcase Inc. Delivers Strong Growth in Q2 Fiscal 2025
- Record Rise in Foreign Holdings of U.S. Treasuries Revealed
- Market Update: Fed's Bold 50 Basis Point Rate Cut Effects
- American Healthcare REIT Announces Major Stock Offering Plans
- Ascendis Pharma's $300 Million Offering: Innovations Ahead
- KeyCorp Adjusts Prime Lending Rate to 8.00 Percent
- Douglas Dynamics Welcomes New COO Amid Executive Changes
- Celebrating NASA's Pioneering Women in Space Exploration
- Dominate the Energy Market: Dominion Energy's Financial Maneuvering
- Trinity Biotech Launches Innovative CGM Technology in India
- Innovative Johnson Controls Metasys Upgrade Enhances Efficiency
- Playtika's Strategic Acquisition of SuperPlay: A Game-Changer
- Parke Bancorp Announces Exciting Cash Dividend for Stockholders
- Caldera Launches Innovative Direct-to-Film Software for 2024
- SciSparc Advances New Treatment for Tourette Syndrome
- Bank of America Approves Preferred Stock Dividends for Q4 2024
- Jerome Powell's Bipartisan Approach to Financial Policy Reform
- Celebrating Hispanic Heritage Month with Community Support
- Recognizing Dr. Patrick M. Tamim: A Pinnacle of Excellence in Vascular Surgery
- Golden Minerals Experiences 52-Week Low Amid Financial Strain
- TriNet's Dividend Announcement Celebrates Company Success
- How Rate Cuts Can Improve Borrowing for U.S. Consumers
- Empowering Future Doctors: Dr. Robert Biter Scholarship Launches
- CFO Insights: PLAYSTUDIOS Stock Sale and Future Prospects
- Informatica's Insider Trading: Key Transactions and Insights
- OptiNose Stock Sale Signals Tax Compliance and Growth Plans
- OptiNose CEO's Stock Sale Signals Market Shifts Ahead
- Informatica Executive Share Sale Sparks Investor Interest
- Esperion Therapeutics' Executive Share Sale: Key Insights
- Cava Group Insider Sells Shares Amid Strong Company Growth
- Dayforce's Strategic Moves Enhance Position in Software Industry
- Sheldon Koenig's Share Sale Signals Changes for Esperion
- Real Good Food Company Faces Nasdaq Delisting Notification
- Exploring Intuitive Machines: Is Now the Time to Invest in LUNR?
- Abacus Life Calculator Hits 150,000 Milestone in Policy Valuations
- ECD Auto Design Welcomes New CFO and Board Changes Amid Growth
- NANOBIOTIX Achieves Critical Milestones in 2024 Financial Progress
- Cellebrite Completes Warrant Redemption and Future Plans
- Citadel Income Fund Increases Monthly Dividend Per Unit to $0.02
- Hydrofarm Holdings Group Receives Nasdaq Compliance Extension
- Great Lakes Dredge & Dock Showcases Growth Strategy at Conference
- Aecon Plans Upcoming Q3 Financial Results and Conference Call
- Exploring Remote Work Habits: Unplugged Productivity Insights